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Background: Increasing evidence suggests that aldosterone promotes renal damage. Since data on the association
between aldosterone and renal function in the general population are sparse, we chose to address this issue. We
investigated the associations between the plasma aldosterone concentration (PAC) or the aldosterone-to-renin ratio
(ARR) and the estimated glomerular filtration rate (eGFR) in a sample of adult men and women from Northeast
Germany.
Methods: A study population of 1921 adult men and women who participated in the first follow-up of the Study
of Health in Pomerania was selected. None of the subjects used drugs that alter PAC or ARR. The eGFR was
calculated according to the four-variable Modification of Diet in Renal Disease formula. Chronic kidney disease
(CKD) was defined as an eGFR <60 ml/min/1.73 m2.
Results: Linear regression models, adjusted for sex, age, waist circumference, diabetes mellitus, smoking status,
systolic and diastolic blood pressures, serum triglyceride concentrations and time of blood sampling revealed
inverse associations of PAC or ARR with eGFR (ß-coefficient for log-transformed PAC −3.12, p < 0.001; ß-coefficient
for log-transformed ARR −3.36, p < 0.001). Logistic regression models revealed increased odds for CKD with
increasing PAC (odds ratio for a one standard deviation increase in PAC: 1.35, 95% confidence interval: 1.06-1.71).
There was no statistically significant association between ARR and CKD.
Conclusion: Our study demonstrates that PAC and ARR are inversely associated with the glomerular filtration rate
in the general population.
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The prevalence of chronic kidney disease (CKD) in-
creases worldwide [1,2]. An impaired renal function is
associated with an increased risk of cardiovascular dis-
ease and mortality [3,4]. In a large longitudinal study [5]
including more than one million subjects from the San
Francisco Bay area, a graded association between the
eGFR and the risk of cardiovascular events and death
was detected. The tight connection between CKD and
cardiovascular risk asks for early detection and monitor-
ing of CKD patients.* Correspondence: anke.hannemann@uni-greifswald.de
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article, unless otherwise stated.CKD and cardiovascular diseases share common risk
factors, such as age, obesity, diabetes mellitus, smoking,
hypertension and dyslipidemia [6]. Increasing evidence
suggests that the renin-angiotensin-aldosterone system
(RAAS) is involved in linking the metabolic syndrome,
CKD and cardiovascular disease [7,8]. Aldosterone, the
final product of the RAAS, plays a major role in the
regulation of intraglomerular and systemic blood pres-
sure [9]. Primary aldosteronism, a condition character-
ized by excessive and largely autonomous aldosterone
secretion, is associated with a high prevalence of renal
damage [10-12]. The deleterious effects of prolonged al-
dosteronism on the kidney include functional changes
(glomerular hyperfiltration) followed by structural changes
that induce glomerular ischemia and renal insufficiency
[12]. The treatment of patients with primary aldosteronismntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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eplerenone or with adrenalectomy may reduce renal dam-
age and prevent cardiovascular events [13].
Beyond the deleterious cardiovascular and renal effects
of excessive circulating aldosterone concentrations [10],
the hormone may also play a role in the development of
renal disease in the general population not suffering
from primary aldosteronism. Since data on the association
between aldosterone and renal function in the general
population are sparse [14-16], we chose to address this
issue. We investigated the associations between the plasma
aldosterone concentration (PAC), or the aldosterone-to-
renin ratio (ARR) and the estimated glomerular filtration
rate (eGFR) in a sample of adult men and women from
Northeast Germany.Methods
The study of health in Pomerania (SHIP)
SHIP is a population-based cohort study in the northeast
of Germany. Study design and sampling methods have
been previously described [17]. In short, 4308 adult men
and women between 20–79 years of age participated in
the baseline examinations (SHIP-0) between October
1997 and May 2001. The first follow-up examination
(SHIP-1) was conducted five years later with 3300 par-
ticipants being re-examined. The present analyses are
based on SHIP-1 data. SHIP is reviewed by an external
scientific review board. All participants gave written in-
formed consent. The study conformed to the principles
of the Declaration of Helsinki as reflected by an a priori
approval of the Ethics Committee of the Board of Physi-
cians Mecklenburg-West Pomerania at the University of
Greifswald.Instruments and measurements
Socio-demographic characteristics and medical histories
of the SHIP-1 participants were obtained by computer-
aided personal interviews. Medication was classified using
the Anatomical Therapeutic Chemical Classification Sys-
tem (ATC) code. Height, weight, and waist circumference
were measured following a standardized protocol. Body
mass index (BMI) was calculated as weight (kg)/height2
(m2). Diabetes mellitus was defined as self-reported physi-
cian’s diagnosis or intake of anti-diabetic medication. Sub-
jects were classified in current smokers and non-smokers
based on self-report. Systolic and diastolic blood pressures
were measured three times on the right arm of seated sub-
jects, using a digital blood pressure monitor (HEM-705CP,
Omron Corporation, Tokyo, Japan). The mean of the sec-
ond and third measurements was used for statistical ana-
lyses. Hypertension was defined as systolic blood pressure
≥140 mmHg or diastolic blood pressure ≥90 mmHg or
self-reported intake of antihypertensive medication.Non-fasting blood samples were taken from the cubital
vein of subjects in the supine position between 8:30 a.m.
and 7:00 p.m. Serum aliquots were stored at −80°C. Serum
triglyceride concentrations were determined enzymatically
on a Hitachi 717. PAC and PRC were measured in EDTA
plasma (PAC: Coat-A-Count Aldosterone, Siemens
Healthcare Diagnostics, Eschborn, Germany; PRC: Renin
III Generation, Cisbio Bioassay, Bagnols-sur-Cèze Cedex,
France). Inter- and intra-assay coefficients of variation of
the PAC assay were 15.7% and 5.4% for low and 3.8% and
2.3% for high concentrations, respectively. Inter- and
intra-assay coefficients of variation of the PRC assay were
5.0% and 3.6% for low and 4.0% and 0.9% for high concen-
trations, respectively. The ARR was calculated as the ratio
of PAC and PRC. Serum creatinine levels were determined
with a modified kinetic Jaffé method (Siemens Dimension
RxL; Siemens Healthcare Diagnostics, Eschborn, Germany).
The eGFR was calculated according to the four-variable
Modification of Diet in Renal Disease formula [18]. CKD
was defined as an eGFR <60 ml/min/1.73 m2 consistent
with the definition of CKD ≥ stage 3 proposed by the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (KDOQI) [19].
Study population
Of the 3300 SHIP-1 participants, all subjects with missing
data on PAC, ARR, or eGFR were excluded from the study
(n = 37). Furthermore, all subjects reporting the intake of
medication that alters PAC or ARR [diuretics, including
aldosterone antagonists, beta blockers or other antiadre-
nergic agents, calcium channel blockers, angiotensin-
converting enzyme (ACE) inhibitors or angiotensin recep-
tor blockers (ARB)] were excluded (n = 1319). Finally, all
subjects with missing information on waist circumference,
diabetes mellitus, smoking status, all pregnant women,
and all subjects with missing data on serum triglyceride
concentrations were excluded (n = 23). This resulted in a
final study population of 1921 subjects (1020 women).
Statistical analyses
We report clinical characteristics of the study population
as proportions for categorical data and as median (1st-3rd
quartile) for continuous data. Group comparisons were
performed with χ2-test (categorical data) or Kruskal-
Wallis test (continuous data). The associations between
PAC or ARR with eGFR were assessed by multivariable
analyses of variance and linear regression models. We re-
port adjusted mean eGFR levels with 95% confidence in-
tervals (CI) according to sex-specific tertiles of PAC or
ARR. Moreover, we report ß-coefficients with standard er-
rors and p-values from the linear regression models. Due
to their skewed distributions, PAC and ARR were log-
transformed before being entered in the linear regression
models. To assess the associations between PAC or ARR
Figure 1 Adjusted mean eGFR according to sex-specific tertiles
of PAC or ARR in 1921 SHIP-1 participants. PAC, plasma
aldosterone concentration; ARR, aldosterone-to-renin ratio. The
multivariable analysis of variance models were adjusted for age, sex,
waist circumference, systolic and diastolic blood pressures, diabetes
mellitus, smoking status, serum triglyceride concentrations, time of
blood sampling, and additionally plasma renin concentration in
models with PAC or ARR as independent variables. The estimated
glomerular filtration rate (eGFR) was calculated according to the
four-variable Modification of Diet in Renal Diseases formula.
Hannemann et al. BMC Nephrology 2014, 15:44 Page 3 of 6
http://www.biomedcentral.com/1471-2369/15/44and CKD, multivariable logistic regression models were
calculated. Odds ratios (OR) and 95% CI for CKD associ-
ated with a one standard deviation (SD) increase in PAC
or ARR are reported. Analyses of variance, linear as well
as logistic regression models were adjusted for sex, age,
waist circumference, diabetes mellitus, smoking status,
systolic and diastolic blood pressures, serum triglyceride
concentrations, and time of blood sampling (before
10.00 a.m., 10.00-11.59 a.m., 12.00-1.59 p.m., 2.00-
3.59 p.m., after 4.00 p.m.). In a sensitivity analysis the
models with PAC as independent variable were addition-
ally adjusted for PRC. P-values <0.05 were considered sta-
tistically significant. All statistical analyses were performed
with SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Our study population comprised 1921 participants, in-
cluding 1020 women (53.1%). The study participants had
a median age of 46.0 years (1st-3rd quartile: 37.0-
58.0 years) and a mean eGFR of 88.1 ml/min/1.73 m2
(1st-3rd quartile: 77.2-100.4 ml/min/1.73 m2). Hyperten-
sion was found in 549 subjects (28.6%). CKD was de-
tected in 74 subjects (3.9%), while 878 subjects (45.7%)
had an eGFR >90 ml/min/1.73 m2. The characteristics of
the study population according to sex-specific PAC or
ARR tertiles are presented in Table 1.
In analyses of variance models, PAC and ARR but not
PRC were inversely associated with eGFR (Figure 1). The
adjusted mean eGFR was significantly lower in subjects
with PAC or ARR in the second or third tertile than in
subjects with PAC or ARR in the first tertile. Linear regres-
sion models confirmed the inverse associations betweenTable 1 Characteristics of the study population
Characteristics
PAC
1. Tertile 2. Tertile 3. Te
Men, % 46.2 48.1 46
Age, years 48 (38–60) 46 (37–59) 44 (36–
Current smokers, % 30.2 34.1 37
Diabetes mellitus, % 3.7 2.4 3
Waist circumference, cm 87.2 (78.1-96.5) 87.5 (79.0-97.0) 89.0 (79
Systolic BP, mmHg 126.0 (115.0-137.5) 127.0 (115.5-139.0) 126.0 (11
Diastolic BP mmHg 80.0 (74.0-86.5) 80.5 (74.5-87.5) 81.0 (74
Triglycerides, mmol/l 1.24 (0.83-1.93) 1.35 (0.92-2.04)* 1.36 (0.9
PAC, ng/l 21.0 (14.0-26.0) 42.0 (36.0-48.0)* 75.0 (61.0
PRC, ng/l 6.6 (4.4-9.8) 7.6 (5.0-11.0)* 9.3 (6.2-
ARR 2.7 (1.8-4.3) 5.4 (3.8-8.2)* 8.4 (5.8-
eGFR, ml/min/1.73 m2 89.1 (78.3-101.9) 88.0 (76.6-101.1) 87.5 (76
ARR, aldosterone-to-renin ratio; BMI, body mass index; BP, blood pressure; eGFR, es
plasma renin concentration.
Data are presented as median (1st-3rd quartile) for continuous variables and as prop
*p < 0.05, 1st vs. 2nd tertile; †p < 0.05 1st vs. 3rd tertile; ‡p < 0.05 2nd vs. 3rd tertile. Gr
tests (continuous variables).PAC or ARR and renal function. The eGFR decreased with
increasing PAC or ARR (ß-coefficient for log-transformed
PAC −3.12, standard error 0.56, p < 0.001; ß-coefficient for
log-transformed ARR −3.36, standard error 0.49, p < 0.001).
The decrease in eGFR with increasing PAC was even more
pronounced (ß-coefficient for log-transformed PAC −3.73,
standard error 0.58, p < 0.001) after additional adjustment
for PRC.
Logistic regression models revealed that increasing
PAC was associated with rising odds for CKD (OR for aARR
rtile 1. Tertile 2. Tertile 3. Tertile
.5 47.0 46.8 46.9
55)†,‡ 45 (37–56) 45 (35–57) 48 (39–60)†,‡
.9† 35.9 34.7 32.0
.5 3.6 2.8 3.1
.0-99.0)† 87.0 (78.1-96.5) 87.1 (78.5-97.0) 90.1 (80.1-98.8)†,‡
5.5-138.0) 123.5 (114.0-136.0) 126.0 (115.0-137.0) 129.5 (117.0-140.5)†,‡
.5-89.0)† 79.0 (73.5-85.3) 80.0 (74.0-87.0) 82.5 (76.0-89.5)†,‡
0-2.02)† 1.27 (0.85-1.93) 1.27 (0.86-1.96) 1.40 (0.95-2.14)†,‡
-98.0)†,‡ 23.0 (15.0-36.0) 44.0 (32.0-59.0)* 61.0 (45.0-88.0)†,‡
14.3)†,‡ 10.3 (6.9-14.8) 8.4 (5.9-11.6)* 5.5 (3.8-7.8)†,‡
12.6)†,‡ 2.5 (1.8-3.1) 5.2 (4.5-6.3)* 10.5 (8.5-14.2)†,‡
.8-99.2)† 91.1 (79.1-104.3) 89.8 (77.9-101.1) 84.5 (75.5-95.8)†,‡
timated glomerular filtration rate; PAC, plasma aldosterone concentration; PRC,
ortion for categorical variables.
oup differences were tested with χ2tests (categorical variables) or Kruskal-Wallis
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additional adjustment for PRC hardly affected the model
(OR for a one SD increase in PAC: 1.34, 95% CI 1.05-
1.70). There were no statistically significant associations
between ARR and CKD (OR for a one SD increase in
ARR: 1.03, 95% CI 0.89-1.20).
Discussion
The main finding of our study is that PAC and ARR are
inversely associated with the eGFR in the general adult
population. These associations were independent of major
risk factors for cardiovascular and renal damage, including
age, sex, diabetes mellitus, smoking status, waist circum-
ference, systolic and diastolic blood pressures, and serum
triglyceride concentrations.
In recent years, experimental and clinical but also obser-
vational studies demonstrated a pathogenic role for aldos-
terone in renal damage [9,20]. Studies in patients with
primary aldosteronism revealed a high prevalence of renal
damage [21,22] and higher rates of albuminuria or protein-
uria than in patients with essential hypertension [10,21,23].
Moreover, in patients with primary aldosteronism serum
aldosterone and potassium concentrations are important
predictors of renal impairment [24]. In primary aldos-
teronism, the adrenal aldosterone secretion is partly au-
tonomous from the RAAS [25]. Patients with primary
aldosteronism present with high circulating aldosterone
and suppressed renin concentrations and elevated
ARRs. Our data provide important new information on
the relation between the RAAS and renal function by
extending previous clinical observations in patients to
the general population. Specifically, our data show that
high PAC and high ARR are associated with decreasing
eGFR. As it is unlikely that a significant proportion of
the study population had primary aldosteronism, the
present study suggests, that high circulating aldosterone
levels within the normal range may have a negative im-
pact on renal function.
Studies investigating the associations between compo-
nents of the RAAS and renal function in the general
population have been rare and produced conflicting re-
sults [14-16]. One large cross-sectional study [16], in-
cluding 9495 outpatient U.S. adults, examined the
associations between PAC, plasma renin activity (PRA)
or ARR with CKD. This study [16] showed that high
PAC (fourth vs. first quartile) or PRA (second to fourth
vs. first quartile) were independently associated with
CKD ≥ stages 3 (eGFR <60 vs. ≥60 ml/min/1.73 m2) and
4 (eGFR <30 vs. ≥60 ml/min/1.73 m2). Furthermore,
subjects with a high ARR (fourth vs. first quartile) had a
decreased OR for CKD ≥ stages 3 and 4. While the ARR
was not significantly associated with CKD in the present
study, we did find an inverse association between the
ARR and eGFR. The different study results with respectto the association between ARR and CKD may be due to
the fact that our study population comprised substan-
tially more healthy subjects than the U.S. study popula-
tion, e.g. the proportions of hypertension or diabetes
mellitus were 28.6% and 3.2%, respectively, in SHIP and
83.1% and 25.8%, respectively, in the U.S. sample [16].
Moreover, there were only few subjects with CKD in our
study sample (3.9%), which may explain why we did not
find an association between ARR and CKD.
Two recent longitudinal studies [14,15] provided evi-
dence for an association between components of the RAAS
and incident CKD. The Framingham Offspring Study [14]
detected a positive association between the serum aldoster-
one concentration and incident CKD. In this study [14],
2345 participants free of CKD were followed over a mean
duration of 9.5 years. In a recent Japanese study [15] 689
men and women were followed over a median duration of
9.7 years. There was no association between PAC and inci-
dent CKD [15] but an inverse association between ARR
and incident CKD [15].
Aldosterone may contribute to renal impairment via dir-
ect and indirect effects. Direct effects are probably medi-
ated through the mineralocorticoid receptor by causing
tubulointerstitial inflammation and subsequent fibrosis
[26,27]. In an experimental study [28], transgenic rats with
increased RAAS activity demonstrated albuminuria and
podocyte damage, which was improved by treatment with
the mineralocorticoid receptor antagonist spironolactone.
Further animal studies [29-31] revealed a role for aldoster-
one in the development of glomerulosclerosis and protein-
uria through thrombotic and proliferative lesions in the
glomeruli and renal vessels. Clinical studies including pa-
tients with primary aldosteronism support the hypothesis
of a direct effect of aldosterone on renal glomerular filtra-
tion in human patients [21,23]. It was shown [23], that pa-
tients with primary aldosteronism had a higher urinary
albumin excretion than patients with essential hyperten-
sion that were matched for mean arterial pressure. In indi-
viduals without primary aldosteronism the situation is less
clear. In patients with heart failure [32] or resistant hyper-
tension [33] aldosterone antagonists were associated with
initial decreases in eGFR and did not alter the decline in
renal glomerular function in the long-term. On the other
side, there is evidence, that aldosterone antagonists exert
renoprotective effects through reduction of albuminuria
or proteinuria [26,34,35]. The addition of aldosterone an-
tagonists vs. placebo to ACE inhibitor treatment was asso-
ciated with a decrease of albuminuria or proteinuria in six
double-blind randomized placebo-controlled clinical trials
[36-41], reviewed in 2010 [26]. Yet, in four [36,38-40] out
of the six studies, the decreases in albuminuria and pro-
teinuria were paralleled by decreases in blood pressure.
Direct aldosterone-induced effects on renal glomerular fil-
tration may thus be limited in comparison to the impact
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are exerted through increases in systemic and intraglomer-
ular blood pressure. It is well known, that high circulating
aldosterone concentrations, even within the physiological
range, predispose persons to an increased risk of hyperten-
sion [42]. High systolic blood pressure, in turn, results in
an increased rate of renal function loss [43]. In the present
study, we observed inverse associations between PAC or
ARR and eGFR despite adjusting for systolic and dia-
stolic blood pressures in the regression models, suggest-
ing that aldosterone may have affected eGFR through
blood pressure-independent mechanisms. Thus, our
data argues for a direct relation between the measures.
Moreover, the relation between PAC and eGFR may be
bidirectional. As kidney function decreases, renal potas-
sium excretion is impaired. The resulting increase in
plasma potassium concentrations in turn may stimulate
aldosterone secretion [44].
Overall, our results provide evidence for an inverse as-
sociation of PAC or ARR with eGFR in the general
population free of medication that alters PAC or ARR.
The impact of PAC or ARR on eGFR in our sample of
adults with mainly normal renal function was statisti-
cally significant but rather small. Clinical implications of
decreasing eGFR with higher PAC or ARR may therefore
be marginal. On the other hand, the association between
PAC or ARR and eGFR is of importance as even a mod-
erately reduced kidney function increases the risk for
cardiovascular disease and mortality [3,6,45].
The present study has several strengths and limita-
tions. Strengths include the population-based design, the
extensive characterization of the SHIP participants and
the standardized data collection by trained and certified
examiners. Limitations arise from the cross-sectional
study design, which does not allow analyzing causality
between the measures. Thus, we cannot assess whether
it is the high PAC that causes the decrease in eGFR or
whether it is the decreased eGFR that leads to the in-
crease in PAC. It might also be questioned whether a
single–occasion measurement of PAC or PRC can ap-
propriately represent the participants’ hormonal status.
Unfortunately, the epidemiological study design did not
allow us to perform repeated blood samplings and hor-
mone measurements. All our data were obtained from
Caucasian subjects. The transferability of our results to
other ethnicities may thus be limited.Conclusion
In conclusion, our study demonstrates that circulating
aldosterone is inversely associated with the glomerular
filtration rate in the general population. Further studies
are warranted to assess the associations between aldos-
terone and CKD in the general population but also todevelop strategies to identify patients who might benefit
from treatment with aldosterone antagonists.
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